Here are four things to know.
1. Pfizer first said it was contemplating strategic options for the unit Oct. 10.
2. Pfizer Consumer Healthcare, which sells common over-the-counter products like Advil, Centrum and ChapStick, represents one of the biggest OTC healthcare products businesses in the world and carries a potential $15 billion-plus price tag.
3. Sources said several companies, including GlaxoSmithKline and Reckitt Benckiser, have already expressed interest in the consumer health unit. Other potential bidders include Procter & Gamble, Sanofi, Johnson & Johnson and Nestle, according to the sources.
4. The auction process will likely extend through next year, with a deal being reached near the middle of 2018, a source told Reuters.
More articles on supply chain:
Pharma’s lobbying efforts: 10 drugmakers that spent the most so far in 2017
FDA announces steps, new guidance to nurture medical device innovations: 4 things to know
Express Scripts sees revenue slip 3% in Q3
